Occupation: Research House
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants.
Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries.
Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584).
Run by a team of highly experienced professionals, our aim is to provide the research of choice for companies, investment banks and institutional investors. We provide independent reports, forecasts and valuations on each company we cover. We help clients gain access to investors, and facilitate feedback from the investment community on companies, their management and strategies. Our research strives to be objective, insightful, financially rigorous, readable and timely.
Web Address: http://www.edisongroup.com
280 High Holborn
Tel: Tel: +44 (0)20 3077 5700
Xcite's farm-out process for Bentley is taking longer than expected, with sluggish market conditions in the North Sea affecting progress. However, with development economics firmly intact, delays to date have only a modest impact on our valuation (our core NAV moves from 181p to 172p), while ultimately securing a farm-out could unlock upside that would increase our core NAV to around 230-270p.
Safinamide has been filed as anticipated in Europe for both early- and late-stage Parkinson's disease (PD). US filing is expected within the next few months. Based on standard review timelines, this should allow for first approval towards the end of 2014, paving the way for launches in early 2015. The filings and any regulatory feedback could help secure additional partners during 2014. Sub-licensing safinamide, particularly…
Condor has delivered the key inputs for a pre-feasibility study that should be completed in Q314. These are positive results from geotechnical and metallurgical studies and an updated resource statement. The 2.4Moz compliant gold equivalent resource hosts over 1.0Moz in the indicated category. Building on statements in the 2012 Annual Report, this could support an initial production programme from open pits recovering some 0.9Moz over…
Fair Value REIT (FVI) reported a solid nine-month operating performance with occupancy levels back to the trend average of 95%. EPRA NAV per share increased 4% to €9.63 from the end of 2012, and EPRA consolidated net profit declined 5% (versus 9M12) reflecting asset disposals. The planned exit from the BBV09 associate at year end is a significant step forward in increasing dividend paying capacity.…
accesso has acquired Siriusware, a leading North American provider of ticketing and point-of-sale (POS) software for $11.8m (c £7.3m) after adjusting for cash acquired. The deal broadens the group's customer base into smaller operators in the leisure and attractions industry, particularly in the ski and snow sports area. It brings to accesso a comprehensive state-of-the-art POS solution, which the group can cross-sell to its customer…